NASDAQ:SBRA - Sabra Health Care REIT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $19.50
Forecasted Upside: 23.50 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
1 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$15.79 As of 09/17/2021 01:00 AM ET

▼ -0.08 (-0.50%)

1 month | 3 months | 12 months

Get New Sabra Health Care REIT Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SBRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBRA

^$19.50

▲ +23.50% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Sabra Health Care REIT in the last 3 months. The average price target is $19.50, with a high forecast of $21.00 and a low forecast of $17.00. The average price target represents a 23.50% upside from the last price of $15.79.

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Sabra Health Care REIT. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
3 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
5 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/21/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/20/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/19/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/13/2021	JMP Securities	Lower Price Target	Market Outperform	$24.00 ➝ $20.00	Low
5/21/2021	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$20.00 ➝ $21.00	Low
5/9/2021	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$17.00 ➝ $21.00	Low
1/13/2021	Mizuho	Downgrade	Buy ➝ Neutral	$18.00	Low
1/13/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$17.00 ➝ $20.00	Low
1/7/2021	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$19.00	Low
12/15/2020	Smith Barney Citigroup	Boost Price Target		$14.00 ➝ $17.00	Medium
12/3/2020	JMP Securities	Upgrade	Market Perform ➝ Outperform	$24.00	Medium
10/2/2020	Mizuho	Boost Price Target	Buy	$14.00 ➝ $16.00	High
9/1/2020	Stifel Nicolaus	Reiterated Rating	Hold	$15.00	High
7/2/2020	Citigroup	Boost Price Target	Neutral	$10.00 ➝ $14.00	Low
6/23/2020	Scotiabank	Upgrade	Sector Underperform ➝ Sector Perform	$12.00 ➝ $15.00	Medium
6/22/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$13.00 ➝ $14.00	Low
6/8/2020	JMP Securities	Initiated Coverage	Market Perform		Low
5/18/2020	Berenberg Bank	Upgrade	Hold ➝ Buy	$15.00	High
4/23/2020	SunTrust Banks	Reiterated Rating	Hold	$15.00	Medium
4/7/2020	Citigroup	Lower Price Target	Neutral	$20.00 ➝ $10.00	High
3/26/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$22.00 ➝ $10.50	Medium
3/23/2020	Bank of America	Downgrade	Neutral ➝ Underperform		Medium
2/26/2020	Mizuho	Upgrade	Neutral ➝ Buy	$22.00	Low
2/6/2020	Barclays	Lower Price Target	Overweight	$26.00 ➝ $25.00	Low
2/5/2020	Berenberg Bank	Initiated Coverage	Hold	$22.00	Medium
12/19/2019	Mizuho	Initiated Coverage	Neutral	$22.00	Medium
12/18/2019	Citigroup	Upgrade	Sell ➝ Neutral	$20.00	High
10/14/2019	Bank of America	Initiated Coverage	Neutral		Low
9/27/2019	JMP Securities	Boost Price Target	Market Outperform	$22.00 ➝ $23.00	Low
9/23/2019	Citigroup	Downgrade	Neutral ➝ Sell	$18.00 ➝ $20.00	Low
9/3/2019	Barclays	Initiated Coverage	Overweight	$24.00	High
2/26/2019	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform		Medium
1/14/2019	BMO Capital Markets	Reiterated Rating	Hold	$17.00	Medium
12/18/2018	SunTrust Banks	Downgrade	Buy ➝ Hold		Medium
11/20/2018	Citigroup	Set Price Target	Hold	$18.00	Low
11/16/2018	Bank of America	Downgrade	Neutral ➝ Underperform	$23.00 ➝ $21.00	Medium
11/16/2018	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium
11/13/2018	Mizuho	Downgrade	Buy ➝ Neutral	$21.00	Medium
9/18/2018	BMO Capital Markets	Initiated Coverage	Market Perform	$24.00	Medium
8/17/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$22.00 ➝ $24.00	Medium
8/13/2018	Mizuho	Reiterated Rating	Buy	$26.00	Low
7/18/2018	Jefferies Financial Group	Reiterated Rating	$21.91	$22.00	Low
6/11/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Market Outperform	$21.00 ➝ $22.00	Low
6/4/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	Medium
6/1/2018	Raymond James	Upgrade	Outperform		Low
5/21/2018	Raymond James	Upgrade	Market Perform ➝ Outperform		High
5/14/2018	JMP Securities	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $21.00	Low
5/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	High
3/26/2018	Bank of America	Upgrade	Underperform ➝ Neutral	$20.00	Medium
3/20/2018	Wells Fargo & Company	Lower Price Target	Market Perform ➝ Market Perform	$24.00 ➝ $19.00	Medium
3/14/2018	Mizuho	Upgrade	Neutral ➝ Buy	$24.00	Low
2/23/2018	Mizuho	Set Price Target	Hold	$18.00	Low
2/22/2018	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$22.00 ➝ $21.00	Medium
1/22/2018	SunTrust Banks	Set Price Target	Buy	$22.00	Low
12/21/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold		Low
12/13/2017	Raymond James	Reiterated Rating	Hold		Medium
11/3/2017	SunTrust Banks	Reiterated Rating	Buy	$25.00	N/A
11/3/2017	Stifel Nicolaus	Reiterated Rating	Hold	$22.00	N/A
10/9/2017	SunTrust Banks	Reiterated Rating	Buy	$30.00	N/A
10/4/2017	Mizuho	Reiterated Rating	Hold	$23.00	Low
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Low
9/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$25.00 ➝ $24.00	Low
9/25/2017	Capital One Financial	Initiated Coverage	Equal Weight	$24.00	Low
9/11/2017	Mizuho	Upgrade	Underperform ➝ Neutral	$23.00 ➝ $24.00	Medium
9/8/2017	Bank of America	Boost Price Target	Underperform	$21.00 ➝ $22.00	Low
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Medium
9/5/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$23.00	Low
8/15/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$25.00	Medium
7/28/2017	Stifel Nicolaus	Reiterated Rating	Hold	$26.00	Medium
7/10/2017	Mizuho	Downgrade	Neutral ➝ Underperform	$25.00 ➝ $23.00	Low
7/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$28.00 ➝ $25.00	Low
6/28/2017	Mizuho	Reiterated Rating	Neutral		Low
5/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$28.00	Low
5/9/2017	Canaccord Genuity	Reiterated Rating	Hold	$26.00	Low
5/8/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	High
2/28/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$25.00 ➝ $30.00	N/A
2/27/2017	Stifel Nicolaus	Boost Price Target	Hold	$24.00 ➝ $26.00	N/A
2/27/2017	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$22.00 ➝ $28.00	N/A
1/31/2017	Jefferies Financial Group	Reiterated Rating	Hold	$25.00	N/A
12/28/2016	JMP Securities	Reiterated Rating	Market Perform		N/A
10/23/2016	Jefferies Financial Group	Reiterated Rating	Hold	$25.00	N/A
10/10/2016	Mizuho	Reiterated Rating	Neutral	$23.00	N/A

(Data available from 9/20/2016 forward)

News Sentiment Rating

1.52 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/22/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/24/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/23/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/23/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/22/2021

7 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/22/2021

4 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/21/2021

14 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/20/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
9/13/2021
Sabra Health Care REIT (NASDAQ:SBRA) PT Lowered to $20.00

Very Positive

americanbankingnews.com
20 hours ago
$153.40 Million in Sales Expected for Sabra Health Care REIT, Inc. (NASDAQ:SBRA) This Quarter
marketbeat.com
20 hours ago
Analysts Anticipate Sabra Health Care REIT, Inc. (NASDAQ:SBRA) Will Announce Quarterly Sales of $153.40 Million
marketbeat.com
9/16/2021
$0.38 EPS Expected for Sabra Health Care REIT, Inc. (NASDAQ:SBRA) This Quarter
marketbeat.com
9/15/2021
Zacks Investment Research Lowers Sabra Health Care REIT (NASDAQ:SBRA) to Sell
americanbankingnews.com
9/13/2021
Sabra Health Care REIT (NASDAQ:SBRA) Releases FY 2021 Earnings Guidance

Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. It focuses on the acquisition, financing and owning real estate property to be leased to third party tenants in the healthcare sector. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.

Today's Range

Now: $15.79

$15.68

$15.96

50 Day Range

MA: $17.01

$15.40

$18.68

52 Week Range

Now: $15.79

$12.86

$19.01

Volume

2,828,600 shs

Average Volume

1,765,047 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

7.60%

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Health Care REIT in the last twelve months: BMO Capital Markets, Jefferies Financial Group Inc., JMP Securities, Mizuho, Smith Barney Citigroup, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for SBRA.

What is the current price target for Sabra Health Care REIT?

6 Wall Street analysts have set twelve-month price targets for Sabra Health Care REIT in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 23.5%. BMO Capital Markets has the highest price target set, predicting SBRA will reach $21.00 in the next twelve months. Smith Barney Citigroup has the lowest price target set, forecasting a price of $17.00 for Sabra Health Care REIT in the next year.
View the latest price targets for SBRA.

What is the current consensus analyst rating for Sabra Health Care REIT?

Sabra Health Care REIT currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBRA will outperform the market and that investors should add to their positions of Sabra Health Care REIT.
View the latest ratings for SBRA.

What other companies compete with Sabra Health Care REIT?

Other companies that are similar to Sabra Health Care REIT include American Tower, Public Storage, Welltower, Weyerhaeuser, Extra Space Storage, Ventas, Medical Properties Trust, CubeSmart, Life Storage, Omega Healthcare Investors, Rayonier, Ryman Hospitality Properties, Healthcare Realty Trust, EPR Properties and PotlatchDeltic.

How do I contact Sabra Health Care REIT's investor relations team?

Sabra Health Care REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is (888) 393-8248 and its investor relations email address is [email protected] The official website for Sabra Health Care REIT is www.sabrahealth.com.